Early detection: POSLUMA is the first FDA-approved radio-hybrid drug for PET imaging of prostate cancers.

[Maxone73]

Imaging tool can detect PCa even with very low PSA levels

news4jax.com/health/2024/01...

[Justfor_]

Trade name for 18F-rhPSMA-7.3 radiopharmaceutical. Its advantage, over the other two previously approved by the FDA, is that it is not excreted through the bladder, thus facilitating better clarity for detection there and about. On the same principal (and even better) the PSMA-1007 scores, but as not approved and commercialized outside Europe it is badmouthed as providing "false positives". Follow the money once more.

"...Recent data suggest that 18F‐labeled PSMA ligands with low urinary excretion (e.g., 18F-PSMA-1007 and 18F-rhPSMA-7.3) can achieve higher detection rates than reported for 68Ga‐labeled PSMA ligands. Our data provide further evidence for this hypothesis, in particular given the results for patients with PSA levels of less than 0.5 ng/mL. In our study, the detection rate for local recurrence was 39% for 18F‐rhPSMA‐7.3, in comparison to only 20% reported in a recently published study of 272 patients undergoing 68Ga‐PSMA‐11 imaging (34)...."

ncbi.nlm.nih.gov/pmc/articl... (2021)

[KocoPr]

I don’t know how that is different from psma pet scan. Seems like the exact same thing, but it obviously isn’t.